Astrocyte Pharmaceuticals Inc.
Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is currently in Phase 2 clinical trials.
Industries
Nr. of Employees
small (1-50)
Astrocyte Pharmaceuticals Inc.
93 Shennecossett Road, Groton, CT 06340
Astrocyte Pharmaceuticals Inc. is currently seeking investment
Astrocyte Pharmaceuticals Inc. is seeking a series-b investment in the range of 1m-5m
Awards
Candidate Acute Traumatic Brain Injury (TBI) Management Capabilities (CATMC) and Acute TBI Diagnostics and Monitoring (ATDM) in Austere Environments
Clinical Phase 1 Development of Battlefield TBI Therapeutic AST-004
Funding (ceiling)
$2,967,845
Award Year
2021
Patents
Compounds and methods for treating neurological and cardiovascular conditions
2025-03-04 • US-12239654-B2
View DetailsCompounds and methods for treating addiction and related disorders
2023-12-12 • US-11839615-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
2022-11-01 • US-11484545-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
2021-03-23 • US-10953031-B2
View Details
Compounds and methods for treating neurological and cardiovascular conditions
2025-03-04 • US-12239654-B2
View DetailsCompounds and methods for treating addiction and related disorders
2023-12-12 • US-11839615-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
2022-11-01 • US-11484545-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
2021-03-23 • US-10953031-B2
View DetailsProducts
Lead small-molecule adenosine A1/A3 receptor agonist candidate (cerebroprotective)
Clinical-stage small-molecule therapeutic candidate that activates astrocyte energy metabolism via receptor-mediated IP3/Ca2+ signaling to enhance mitochondrial ATP production and reduce acute brain injury; developed as an intravenous formulation for emergency administration with an oral formulation in preclinical development.
Additional small-molecule CNS candidates (preclinical)
Other CNS-directed small-molecule programs in preclinical development including candidates for pain/migraine and additional CNS indications.
Lead small-molecule adenosine A1/A3 receptor agonist candidate (cerebroprotective)
Clinical-stage small-molecule therapeutic candidate that activates astrocyte energy metabolism via receptor-mediated IP3/Ca2+ signaling to enhance mitochondrial ATP production and reduce acute brain injury; developed as an intravenous formulation for emergency administration with an oral formulation in preclinical development.
Additional small-molecule CNS candidates (preclinical)
Other CNS-directed small-molecule programs in preclinical development including candidates for pain/migraine and additional CNS indications.
Expertise Areas
- Cerebroprotection and neuroprotection
- Translational preclinical neuroscience
- Clinical trial management for acute neurological indications
- Small-molecule drug discovery for central nervous system (CNS) targets
Key Technologies
- Adenosine receptor pharmacology (A1/A3-targeted agonists)
- IP3/Ca2+-mediated mitochondrial activation assays
- Nonhuman primate transient middle cerebral artery occlusion (tMCAO) model
- Rodent TBI models (pneumatic impact, photothrombosis)
Key People
Co-Founder and Chief Executive Officer
Co-Founder and Advisor
Vice-President of Research
Chief Medical Advisor
Vice-President of Clinical Development Operations
Co-Founder and Chief Executive Officer
Co-Founder and Advisor
Vice-President of Research
Chief Medical Advisor
Vice-President of Clinical Development Operations
Featured In Technology Showcase
Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004
Astrocyte Pharmaceuticals has begun a Phase 1 trial for AST-004, a potential treatment for stroke, TBI, and neurodegenerative diseases. The study, funded partly by MTEC and the U.S. Army, will assess safety in 52 healthy participants. If successful, it will progress to Phase 2 trials.
News & Updates
Astrocyte Pharmaceuticals was named 'Innovator of the Month' by Senator Chris Murphy for their work in advancing cerebroprotective therapies.
Astrocyte Pharmaceuticals received FDA clearance for its Investigational New Drug Application for AST-004, paving the way for Phase 2 trials.
The Alzheimer’s Drug Discovery Foundation joined Astrocyte Pharmaceuticals’ $6M+ pre-Series B financing round to expand the development of AST-004.
Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Innovation and Progress Award from the journal Stroke for his work on AST-004.
Astrocyte Pharmaceuticals was named 'Innovator of the Month' by Senator Chris Murphy for their work in advancing cerebroprotective therapies.
Astrocyte Pharmaceuticals received FDA clearance for its Investigational New Drug Application for AST-004, paving the way for Phase 2 trials.
The Alzheimer’s Drug Discovery Foundation joined Astrocyte Pharmaceuticals’ $6M+ pre-Series B financing round to expand the development of AST-004.
Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Innovation and Progress Award from the journal Stroke for his work on AST-004.